In addition to the induction of increased number of tumor-specific T cells, the use of Th1-polarized αDC1s with selectively elevated ability to attract effector (rather than regulatory T cells) and to induce the IL-12-dependent effector (CTL) pathway of differentiation in CD8+ T cells may help to induce tumor-specific immunity of a more desirable pattern than that induced by whole tumor cells or standard non-polarized sDCs (29,30). The gene discussed is CD8A; the disease is neoplasm.